recombinant glp 1 Targeting GLP-1, GIP & GCG in Obesity and Type 2 Diabetes Research encompassing amino acids 7 Engineered GLP-1R-targeting nanoplatforms: multimodal therapeutics

Do you expect the trend to continue and market access to ease more

The average participant lost about 26 pounds, decreasing from 255 to 229 pounds or approximately 10% of their body weight

Monotherapy with the once weekly GLP-1 receptor agonist dulaglutide for 12 weeks in Japanese patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomised, double-blind, placebo-controlled study

We also have randomized evidence in alcohol use disorder

Nitrous oxide litigation continues to grow against manufacturers and distributors as lawmakers intensify efforts to restrict access to the recreational products commonly marketed as whippets. New regulatory proposals reflect growing concern that flavored, high-capacity nitrous oxide canisters are being widely sold for recreational use despite well-documented neurological risks